round 75 per cent of those who take their own lives are in low and middle-income countries. The WHO’s response to this alarming fact has been to promise a rapid scale-up of access to anti-depressants and anti-psychotics. The problem with this solution, Rachel Aviv suggests in , is that modern psychiatry was ‘not designed to address the kinds of ailments that arise from being marginalized or oppressed for generations’. Further, the promotion of pharmaceuticals over
